Targeted Strategies for Today's Evolving Markets

MissionIR Blog

MissionIRNewsBreaks – iClick Interactive Asia Group Limited (NASDAQ: ICLK) Receives 3 Accolades from TopDigital China 2020

iClick Interactive Asia Group (NASDAQ: ICLK), an independent online marketing and enterprise data solutions provider in China today announced its receipt of three accolades in “The 8th TopDigital China 2020” awards competition. According to the update, the honors include the “DTC Branding Campaign Award” for the lululemon New Year’s Season Promotion campaign, the “E-commerce Content Marketing Award” for Nike’s “Joyride” campaign and the Bronze award under the “KOL Marketing” category for Zippo’s Valentine’s Day social campaign. “It is a great honor to receive these awards from TopDigital,” Jian “T.J.” Tang, CEO and co-founder of iClick, stated in the news release. “This is an affirmation of iClick’s ability to leverage pioneering marketing innovations to help our clients drive exceptional business growth. I am confident that more and more brands will look to our online offline integration-oriented, highly customized Enterprise Solutions and performance-based Marketing Solutions to drive sales as customers increasingly desire more personalized offerings to fit their purchasing needs.”

To view the full press release, visit http://ibn.fm/skQ8l

About iClick Interactive Asia Group Limited

iClick Interactive Asia Group Limited (NASDAQ: ICLK) is an independent online marketing and enterprise data solutions provider that connects worldwide marketers with audiences in China. Built on cutting-edge technologies, its proprietary platform possesses omni-channel marketing capabilities and fulfils various marketing objectives in a data-driven and automated manner, helping both international and domestic marketers reach their target audiences in China. Headquartered in Hong Kong, iClick was established in 2009 and is currently operating in ten locations worldwide including Asia and Europe.

For more information, please visit ir.i-Click.com.

NOTE TO INVESTORS: The latest news and updates relating to ICLK are available in the company’s newsroom at http://ibn.fm/ICLK

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in iClick Interactive Asia Group Ltd. ICLK, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Pressure BioSciences, Inc. (PBIO) to Host Teleconference to Discuss Q1 2020 Results and Provide Business Update

Pressure BioSciences (OTCQB: PBIO) on Tuesday announced that it will host a teleconference to discuss its first quarter 2020 financial results and to provide a business update, including the Company’s progress made in the development of its Ultra Shear Technology(TM) (“UST(TM)) Platform and in the pending merger of PBI, Cannaworx, and SkinScience Labs. The call is scheduled to take place at 4:30 p.m. Eastern Time on July 8, 2020. Interested parties may join the conference by dialing (844) 602-0380 (North America) or (862) 298-0970 (International) and entering verbal passcode: PBI First Quarter 2020 Financial Call & Business Update. For those unable to participate in the live teleconference, a replay will be available beginning Thursday, July 9, 2020, and will be accessible for 30 days via telephone and the Company’s website.

To view the full press release, visit http://ibn.fm/9486F

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the development and sale of innovative, broadly enabling, pressure-based solutions for the worldwide life sciences and other industries. Its products are based on the unique properties of both constant (i.e., static) and alternating (i.e., pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented enabling technology platform that uses alternating cycles of hydrostatic pressure between ambient and ultra-high levels to control biomolecular interactions safely and reproducibly (e.g., cell lysis, biomolecule extraction). The Company’s primary focus is in the development of PCT-based products for biomarker and target discovery, drug design and development, biotherapeutics characterization and quality control, soil & plant biology, forensics, and counter-bioterror applications. Additionally, major new market opportunities have emerged in the use of its pressure-based technologies in the following areas: (1) the use of its recently acquired, patented technology from BaroFold, Inc. (the “BaroFold” technology) to allow entry into the bio-pharma contract services sector, and (2) the use of its recently-patented, scalable, high-efficiency, pressure-based Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher quality, homogenized, extended shelf-life or room temperature stable low-acid liquid foods that cannot be effectively preserved using existing non-thermal technologies. For more information, visit www.PressureBioSciences.com.

NOTE TO INVESTORS: The latest news and updates relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, Pressure BioSciences Inc. PBIO | Leave a comment

MissionIRNewsBreaks – Cybin Corp. and IntelGenx Corp. to Collaborate in Development of Fast-Acting Psilocybin Film

Cybin Corp., Canada’s premier mushroom life sciences company focused on advancing psychedelic and nutraceutical-based products derived from fungi, today announced its entry into a feasibility agreement with IntelGenx Corp. (OTCQB: IGXT) (TSX-V:IGX) for the development of an orally-dissolving film for the delivery of pharmaceutical-grade psilocybin, subject to receipt of all necessary regulatory approvals. “We at Cybin are proud to be working with IntelGenx to develop a fast-acting psilocybin film,” Cybin’s Chief Medical Officer, Dr. Jukka Karjalainen, stated in the news release. “Compared to oral psilocybin capsules, which are subject to variable intestinal absorption and high first-pass metabolism in the liver, the systemic bioavailability of orally-dissolving psilocybin film is expected to be quite high. In addition, the dose of psilocybin administered by an orally-dissolving film is expected to be a fraction of what is required in oral capsules. Taken together, these features have the potential to increase both the safety and efficacy of psilocybin when administered in this manner.”

To view the full press release, visit http://ibn.fm/qQ9zh

About Cybin

Cybin is a mushroom life sciences company advancing psychedelic and nutraceutical-based products. The Company expects to launch psilocybin-based products in jurisdictions where the substance is not prohibited. Simultaneously, the Company is structuring and supporting clinical studies across North America and other regions, through strategic academic and institutional partnerships. For more information, visit www.Cybin.com.

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks | Tagged | Leave a comment

DarioHealth Corp. (NASDAQ: DRIO) is “One to Watch”

  • Dario’s popular (4.9 stars on the Apple App Store and 11,000 reviews) chronic condition management platform addresses a $72 billion annual U.S. market opportunity
  • There are roughly 51,000 active users of the Dario platform, including its proprietary medical device, mobile application, and digital and human coaching services
  • Clinical studies show Dario’s direct improvement on users’ health measures like H1AC scores (diabetes) and blood pressure (hypertension)
  • Patient engagement in therapies leads to health success. The Dario platform centers on continual maximization of patient engagement through personalization, including ‘nudges’ and live, AI-generated responses to health measures provided by Dario smartphone-connected medical devices
  • Dario is now deploying its successful B2C platform in B2B channels, targeting employers and health plans with competitive advantages spanning cost, software and hardware
  • Catasys Inc.’s (NASDAQ: CATS) C-level team (president, CMO, and head of sales) recently joined Dario to accelerate B2B penetration and revenue growth

New York and Israel-based DarioHealth (NASDAQ: DRIO) leads global digital therapeutics (“DTx”) with its popular, smartphone-centered personalized chronic illness management software-as-a-service (SaaS). The company’s strategic advantages include:

  • AI-powered digital solutions that drive durable behavior change in chronic disease patients, and
  • Personalized user experience at scale to make behavior change the path of least resistance.

Approximately $3 trillion in annual U.S. costs associated with chronic illnesses like diabetes, hypertension and obesity are largely preventable with behavioral therapies. Formerly limited to periodic office visits, these therapies can now scale to millions with tech-enabled, continual and remote health monitoring, as well as AI-driven digital and live coaching. This is all possible while still maintaining the personalization required for success in reducing illness and its related effects and costs.

Roughly 51,000 active, paying users manage their health with Dario’s platform that combines smartphone-connected vitals measurement, remote patient monitoring (“RPM”), lifestyle management tools, and AI-driven and human coaching to deliver improved clinical outcomes.

Among the most downloaded medical apps, the Dario platform is rated at 4.9 stars on the Apple App Store and features 11,000 reviews, along with a Net Promoter Score (a measurement of consumers’ willingness to recommend the product to others) that’s the highest in its field.

Company Strategy

Clinical studies demonstrate Dario’s direct improvement on users’ health measures like H1AC scores (diabetes) and blood pressure (hypertension).

Patient engagement in therapies leads to health success. Dario’s platform centers on continual maximization of patient engagement through personalization, including ‘nudges’ and live, AI-generated responses to health measures provided by Dario’s smartphone-connected medical devices.

Proprietary data analysis provides valuable insights that not only improve health care providers’ medical capabilities but, through artificial intelligence, encourage patients to take evidence-based and highly personalized preventative measures that reduce risk, emergency room visits and preventable hospitalization.

Dario is now deploying its successful B2C platform in B2B2C, targeting employers and health plans with competitive advantages in cost, software and hardware.

The company estimates an annual addressable U.S. market of $72 billion, only 1% of which has been penetrated with digital therapeutics.

The strategic transition to B2B2C (from exclusively B2B) is intended to accelerate revenue growth by reducing Dario’s cost per acquisition per user and expanding margins.

Dario’s commitment to aggressive growth is also shown by its appointment of a new president, chief medical officer and head of sales for North America, all from a highflyer behavioral health company.

Key growth drivers planned include expansion of the company’s paying B2C subscriber base; lateral expansion into other chronic conditions that overlap with its core diabetes populations, such as hypertension, obesity and depression; and increased B2B2C penetration.

Financial Highlights

The company plans to leverage a massive opportunity for growth, with a global addressable market for digital therapeutics of roughly $108 billion. In the U.S. alone, that number is estimated at $72 billion, and only about 1% of that market has been penetrated.

Dario’s strategic transition to an SaaS membership business model increased gross profit by 87% in Q1 2020, as compared to the prior year. Membership revenue increased from 27.1% to 46.7% in the same period. The company is seeing improved operating efficiencies as it shifts focus to the B2B2C business model, and it expects average revenue per user per month (“ARPU”), which was $6 and $25 in 2019 and 2020, respectively, to reach $70.

Value to Consumers and Businesses

Dario continually evaluates and optimizes the value and return its platform delivers to consumers and businesses.

Consumers seeking to understand how their everyday behavior impacts their personal health and chronic conditions benefit from actionable feedback on how to improve health and better collaborate with health care providers.

Businesses looking to increase employee satisfaction, loyalty and productivity with fewer health-related absences take advantage of Dario’s services for employers.

Health care providers improve patient compliance using the platform’s interactive services that allow for greater monitoring, which improve engagement with patients at the right times and with the right treatments.

Health plans can leverage DarioHealth’s solutions to improve patient outcomes and lower costs.

Recent Studies

The company recently presented the results of two new studies at the American Diabetes Association’s 80th Scientific Sessions, which showed sustained improvements in blood glucose levels and blood pressure among users of its digital therapeutic platform for chronic diseases. The results of these two studies demonstrate that the use of Dario’s therapeutic platform promotes behavioral modification, enhanced individual engagement and improved clinical outcomes.

Remote Patient Monitoring (“RPM”) Agreements

The Centers for Medicare & Medicaid Services recently approved RPM codes for Medicare patients, which enables physicians to bill for between-visit patient care.

This simplifies implementation of the company’s open and scalable AI-driven platform and further supports transition to the company’s high-margin, recurring SaaS model targeting B2B2C revenue channels.

Emergency COVID-19 FDA Guidelines Allow Self-Test Blood Glucose Meters

In an effort to preserve personal protective equipment (“PPE”) and reduce contact between health care providers and patients in hospital settings due to COVID-19, the U.S. Food and Drug Administration (“FDA”) has recognized that home-use blood glucose meters, including Dario’s smartphone-connected metering device, may be used by patients with diabetes who are hospitalized due to COVID-19 to check their own blood glucose levels and provide the readings to the health care personnel caring for them.

As a result, hospitals can now allow patients to self-test using their Dario blood glucose testing strips and smartphone-connected devices, or hospitals can issue patients Dario devices upon admission for COVID-19-related conditions.

Irregularities in blood glucose levels are suspected as a factor in the increased severity of potentially deadly COVID-19 complications. As such, a high priority is being placed on stabilization of patients’ blood glucose levels.

Awards and Recognition

DarioHealth’s Blood Glucose Monitoring System was voted as the ‘Best Glucometer for Data Management’ by Top Ten Reviews. Jeph Preece, senior editor at Top Ten Reviews, said, “The Dario app is the best data management system that I’ve seen. Compared to apps by popular brands, Dario’s system looks and feels like it’s years ahead of the curve.”

‘The Global Digital Health 100’, an annual award sponsored by the reputable Journal of Health, recognized DarioHealth as a leader among health technology companies demonstrating the greatest potential to change the way that health care is delivered.

For more information, visit the company’s website at www.DarioHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to DRIO are available in the company’s newsroom at http://ibn.fm/DRIO

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in DarioHealth Corp. DRIO | Leave a comment

MissionIRNewsBreaks – iClick Interactive Asia Group Limited (NASDAQ: ICLK) Recognized as “Asia Pacific’s Leader in Smart Marketing Solutions” by Mediazone Group

iClick Interactive Asia Group (NASDAQ: ICLK), an independent online marketing and enterprise data solutions provider in China, today announced that it was named “Asia Pacific’s Leader in Smart Marketing Solutions” at the Mediazone Group’s “Asia’s Most Valuable Service Providers Awards 2020.” The Company also garnered Certificates of Merit for “Excellence in Marketing Technologies, China-Market Solutions and Project Management and Customer Services.” “We are thrilled to receive these accolades from Mediazone which represent a strong international recognition of our data analytics and integrated solutions,” Frankie Ho, Head of International Business of iClick, stated in the news release. “We remain devoted to evolving our integrated Marketing and Enterprise Solutions to provide our clients with best-in-class support and help them effectively capture opportunities in their fast-changing markets and rapidly expand into international markets.”

To view the full press release, visit http://ibn.fm/WcltE

About iClick Interactive Asia Group Limited

iClick Interactive Asia Group Limited (NASDAQ: ICLK) is an independent online marketing and enterprise data solutions provider that connects worldwide marketers with audiences in China. Built on cutting-edge technologies, its proprietary platform possesses omni-channel marketing capabilities and fulfils various marketing objectives in a data-driven and automated manner, helping both international and domestic marketers reach their target audiences in China. Headquartered in Hong Kong, iClick was established in 2009 and is currently operating in ten locations worldwide including Asia and Europe.

For more information, please visit ir.i-Click.com.

NOTE TO INVESTORS: The latest news and updates relating to ICLK are available in the company’s newsroom at http://ibn.fm/ICLK

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in iClick Interactive Asia Group Ltd. ICLK, MissionIRNewsBreaks | Leave a comment

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) Completes Acquisition of Quantitative Medicine LLC

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced it has completed its acquisition of Quantitative Medicine LLC (“QM”), a biomedical analytics and computational biology company, in an all-stock transaction valued at approximately $1.8 million. Cofounded by Drs. Robert Murphy and Joshua Kangas, both of Carnegie Mellon University’s Computational Biology Department, QM developed its novel, computational drug-discovery platform CoRETM, an innovative machine learning platform that predicts the main effects of drugs on target molecules that mediate disease, which is expected to dramatically reduce the time, cost and financial risk of discovering new therapeutic drugs. “This acquisition will enable us to further leverage our unique database of drug-response and genomics profiles that our subsidiary, Helomics, has gathered from more than 150,000 cancer cases over more than 10 years of clinical testing,” Dr. Carl Schwartz, Predictive Oncology’s CEO, stated in the news release. “Integrating QM’s proven machine learning platform, CoRE, with our proprietary database of drug response and genomics profiles is expected to revolutionize the role of our AI-driven predictive models in the discovery and development of new anti-cancers. We will be able to more quickly understand how specific types of tumors react to cancer drug therapies. This will allow our customers to accelerate the development and commercialization of personalized patient treatments that dramatically improve patient outcomes. We intend to offer this new capability to our pharmaceutical company customers in revenue generating projects this year.”

To view the full press release, visit http://ibn.fm/TUszu

About Predictive Oncology Inc.

Predictive Oncology (NASDAQ: POAI) operates through three segments (Domestic, International and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor(TM), patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s Skyline Medical division markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, Predictive Oncology Inc. POAI, Small Cap News | Leave a comment

Predictive Oncology Inc. (NASDAQ: POAI) Announces Acquisition of Soluble Therapeutics, BioDtech as it Continues Buildout of Precision Medicine Business

  • Predictive Oncology announced the acquisition of Soluble Therapeutics Inc. & BioDtech Inc.
  • Acquired companies seek to enhance drug development process through the optimization of protein solubility and stability as well as through detection, removal of endotoxins
  • The companies were acquired for consideration amounting to 125,000 common shares and waiving of $1.07 million promissory note issued by parent company, InventaBioTech
  • Predictive Oncology seeks to build out its precision medicine business line, aimed at helping clinicians individualize cancer treatment

Predictive Oncology (NASDAQ: POAI), a knowledge-driven medicine company that focuses on applying data and artificial intelligence (“AI”) to cancer personalized medicine and drug discovery, announced that it had completed the acquisition of Soluble Therapeutics Inc. and BioDtech Inc. (http://ibn.fm/ccEdD). The company revealed that it had purchased the assets of Soluble and BioDtech, including certain intellectual property relating to contract research organization (“CRO”) services and equipment from parent company InventaBioTech for a total consideration of 125,000 shares of common stock. As part of the transaction, Predictive Oncology also waived all of the remaining amounts due and payable to the company under a secured promissory note of InventaBioTech in the principal amount of $1,070,000 relating to advances made by the company in 2017.

The acquisition of Soluble Therapeutics and BioDtech marks a new step in Predictive Oncology’s journey towards building out its precision medicine business, following its acquisition of its Helomics arm in April 2019. Soluble Therapeutics, which was founded in 2008 with the aim of commercializing technology licensed from the University of Alabama at Birmingham, seeks to enhance the drug development process by rapidly optimizing protein solubility and stability. Meanwhile, BioDtech develops and markets a line of reagents and systems for the detection, neutralization and removal of endotoxin for researchers in the bioresearch and bioprocess fields.

“These two acquisitions meaningfully expand revenue and monetization prospects for our precision medicine business,” said Predictive Oncology CEO and director Dr. Carl Schwartz (http://ibn.fm/4Nk9J). “First, the Soluble Therapeutics assets increase the company’s capabilities to provide services for the pharmaceutical and biotech industries and predict and provide the best formulation with the highest concentration and the most stable solution for protein and peptide-based drugs. Second, the company’s purchase of BioDtech’s assets provides it with ownership over BioDtech’s successfully developed test used to ‘unmask’ endotoxins, which allows a monitoring physician to perhaps change the strategy of treatment or treat the patient with antibiotics. These acquisitions will allow Predictive Oncology to further maximize opportunities within the company’s precision medicine business.”

Predictive Oncology is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through its Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a roadmap to help individualize therapy. In addition, the company is leveraging artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow.

For more information, visit the company’s website at www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Predictive Oncology Inc. POAI | Leave a comment

MissionIRNewsBreaks – Wrap Technologies, Inc. (NASDAQ: WRTC) Secures BolaWrap(R) Purchase Orders from Police Agencies in Texas, Illinois and Michigan

Wrap Technologies (NASDAQ: WRTC), an innovator of modern policing solutions, today announced its receipt of purchase orders for BolaWrap devices, cartridges and accessories from police agencies in Texas, Illinois and Michigan. According to the update, the Company has received more than 250 requests from law enforcement agencies for quotes, training and demonstrations since June 1, 2020, and these are beginning to translate into purchase orders. “The BolaWrap gives us an option before going to impact weapons,” Chief Matt Magill of Lanark Police Department in Illinois stated in the news release. “It gives us that time period where we can safely go hands on, especially for those who are passively resistant or are mentally ill, and you don’t have to take to it to the next level of force.”

To view the full press release, visit http://ibn.fm/f3yFx

About Wrap Technologies (NASDAQ: WRTC)

Wrap Technologies is an innovator of modern policing solutions. The Company’s BolaWrap 100 product is a patented, hand-held remote restraint device that discharges an eight-foot bola style Kevlar(R) tether to restrain an individual at a range of 10-25 feet. Developed by award winning inventor Elwood Norris, the Company’s Chief Technology Officer, the small but powerful BolaWrap 100 assists law enforcement to safely and effectively control encounters, especially those involving an individual experiencing a mental crisis. For information on the Company please visit www.WrapTechnologies.com. Examples of recent media coverage are available as links under the “Media” tab of the website.

NOTE TO INVESTORS: The latest news and updates relating to WRTC are available in the company’s newsroom at http://ibn.fm/WRTC

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, Wrap Technologies Inc. WRTC | Leave a comment

MissionIRNewsBreaks – Trxade Group, Inc.’s (NASDAQ: MEDS) Bonum Health Names New President

Trxade Group (NASDAQ: MEDS), an integrated drug procurement, delivery and healthcare platform, recently announced the appointment of Ashton Maaraba as president of Trxade Group’s Bonum Health telemedicine practice. An article discussing the company reads, “Maaraba has over 20 years of experience in developing and directing strategic national sales, marketing and operating initiatives in ever-changing, dynamic environments, according to the company, and will work to help build long-term shareholder value by welcoming a growing number of patients under the Bonum Health Hub platform. . . . ‘Ashton is an intuitive leader with acute business acumen and expertise in channel development and market development,’ Trxade Group CEO Suren Ajjarapu stated in describing the company’s forward strategy (http://ibn.fm/MDB3I). ‘I am confident in his ability to drive widespread adoption of Bonum Health amongst both employers seeking to provide unique healthcare perks to their workers as well as to individuals seeking a low-cost, convenient way to speak with a doctor.’”

To view the full article, visit http://ibn.fm/HsqD2

About Trxade Group, Inc.

Headquartered in Tampa, Florida, Trxade Group, Inc. (NASDAQ: MEDS) is an integrated drug procurement, delivery and healthcare platform that fosters price transparency, thereby improving profit margins for both buyers and sellers of pharmaceuticals. Trxade Group operates across all 50 states with the central mission of making healthcare services affordable and accessible. Founded in 2010, Trxade Group is comprised of four synergistic operating platforms; (1) the Trxade B2B trading platform with 11,400 registered pharmacies, (2) Integra Pharma Solutions, Trxade Group’s virtual wholesale division, (3) the Bonum Health platform offering affordable telehealth services; and (4) the DelivMeds app, which coordinates a nationwide distribution network through independent pharmacies or mail order delivery. For additional information, please visit www.Trxade.com, www.DelivMeds.com and www.BonumHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in MissionIRNewsBreaks, Trxade Group Inc. (MEDS) | Leave a comment

MissionIRNewsBreaks – Energy Fuels Inc. (NYSE American: UUUU) (TSX: EFR) Supporting Clean Energy with Alternate-Feed Material Recycling Program

Energy Fuels (NYSE American: UUUU) (TSX: EFR), the leading uranium producer in the United States, continues to support the use of clean energy through its alternate-feed material recycling program. An article discussing the company reads, “Besides recycling uranium, Energy Fuels also recycles vanadium. In addition to being the only conventional uranium mill in the U.S., the White Mesa Mill is the only conventional vanadium mill in the country. Vanadium is used in steel, titanium and other high-strength alloys. The mineral is also being increasingly used in high-capacity, community-scale batteries that store intermittent renewable energy sources, such as wind and solar. . . . In 2019, Energy Fuels recycled 1.8 million pounds of vanadium. This is enough vanadium used in steel to build four and a half Golden Gate Bridges from scratch. And now, the company is entering the rare earth elements (‘REE’) space, which also involves the recycling of REE-bearing materials. Indeed, the White Mesa Mill may be able to play an important role in bringing REE production back to the U.S.

To view the full article, visit http://ibn.fm/fGUfb

About Energy Fuels

Energy Fuels is a leading U.S.-based uranium mining company, supplying U3O8 to major nuclear utilities. The company also produces vanadium from certain of its projects, as market conditions warrant. Its corporate offices are near Denver, Colorado, and all of its assets and employees are in the United States. Energy Fuels holds three of America’s key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch in-situ recovery (“ISR”) Project in Wyoming and the Alta Mesa ISR Project in Texas. The White Mesa Mill is the only conventional uranium mill operating in the United States today, has a licensed capacity of over 8 million pounds of U3O8 per year, and has the ability to produce vanadium when market conditions warrant. The Nichols Ranch ISR Project is on standby and has a licensed capacity of 2 million pounds of U3O8 per year. The Alta Mesa ISR Project is also currently on standby. In addition to the above production facilities, Energy Fuels has one of the largest NI 43-101 compliant uranium resource portfolios in the U.S., including several uranium and uranium/vanadium mining projects on standby and in various stages of permitting and development. The primary trading market for Energy Fuels’ common shares is the NYSE American under the trading symbol UUUU; the company’s common shares are also listed on the Toronto Stock Exchange under the trading symbol EFR. For more information, visit the company’s website at www.EnergyFuels.com.

NOTE TO INVESTORS: The latest news and updates relating to UUUU are available in the company’s newsroom at http://ibn.fm/UUUU

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Posted in Energy Fuels Inc. UUUU, MissionIRNewsBreaks | Leave a comment